Surgerii Secures Series C3 Financing Led by ZhenXin Valley to Advance Global Leadership in Minimally Invasive Surgical Robotics

VCBeat (WeChat: vcbeat) has learned that Beijing Shurui Technology Co., Ltd. (“Shurui” or the “Company”) recently announced the completion of its C3 round financing, amounting to hundreds of millions of RMB. The round was led by Loyal Valley Capital, with full support from existing shareholders such as Vertex Ventures China and SDIC Investment Promotion, and participated by Denuo Capital, Xinyi Investment, and Sanya Cuihu.

This round of financing will continue to support the clinical trials and market promotion of SHURUI’s existing flagship products across multiple departments both domestically and internationally, as well as the research and development of next-generation products. Meanwhile, the company will further strengthen its global commercialization layout, comprehensively enhance its competitive advantages in the global surgical robotics field, collaborate with top-tier hospitals to continuously expand indications and application departments, drive collaborative innovation, and usher in a new era of single-port surgery.

Professor Xu Kai, Shanghai Jiao Tong University, Founder of SHURUIIt was stated that as surgical approaches have evolved from open surgery to multi-port laparoscopy, then to single-port laparoscopy, and even to natural orifice surgery, patient trauma has gradually decreased while the technical difficulty of procedures has continuously increased. Therefore, leveraging robotic technology to assist surgical operations and enhance visual intuition and precision has become an inevitable trend. Since its establishment, SHURUI Robotics has adhered to its mission of “extreme minimally invasiveness, bringing minimally invasive surgical solutions closer to patients.” Relying on its core proprietary technology—the deformable dual-continuum mechanism—and in collaboration with top-tier hospitals, SHURUI has pioneered a variety of innovative surgical techniques. These advancements allow patients to preserve organ function to a greater extent while undergoing less traumatic procedures, truly benefiting patients. Moreover, the flexible, precise, safe, and stable operational performance of SHURUI Robotics has garnered high recognition from numerous experts in China.

We extend our sincere gratitude to all institutional investors for their support and trust in SHURUI. Guided by the clinical needs of physicians and patients, the Company is committed to delivering safer, less invasive, and more precise minimally invasive surgical solutions. We aim to empower hospitals with future smart operating rooms centered on surgical robots, striving to become a technological pioneer and market leader in the field of laparoscopic surgical robotics.

Lead Investor in This Round: Loyal Valley CapitalIt was stated that in the execution of surgical procedures, ranging from open surgery to laparoscopic minimally invasive techniques, robotic technology has consistently proven to be a more effective modality. Currently, SHURUI’s core technology features snake-like robotic arms, which offer superior flexibility and force load capacity compared to the rigid wire-driven arms of traditional surgical robots, while also resolving the “chopstick effect” associated with conventional single-port approaches. Loyal Valley Capital (LVC) believes that urgent patient needs are driving medical technology beyond mere domestic substitution, marking a shift from an era of “low cost” to one prioritizing “quality first.” With its technological innovation and mission to stay close to patient needs, SHURUI stands out in the global surgical robotics landscape. Although the company started with single-port surgical robots, its ambitions extend far beyond this niche. It is our hope that SHURUI’s innovative technologies will benefit patients worldwide by meeting their demands for shorter recovery times and optimal cosmetic outcomes.

SHURUI is a high-tech medical device company dedicated to the independent research and development, production, and sales of laparoscopic surgical robot systems with globally leading technological advantages, as well as associated surgical instruments and consumables. The company possesses core independent intellectual property rights and full-chain key core technologies, holding nearly 600 intellectual property rights and applications worldwide, thereby establishing a comprehensive independent intellectual property protection system. It has successively gained support and recognition from national and local government bodies—including the Ministry of Industry and Information Technology, the Ministry of Science and Technology, the Beijing Municipal Science & Technology Commission, and Zhongguancun—as well as numerous investment institutions.

After eighteen years of dedicated refinement, Professor Xu Kai, founder of SHURUI Robotics, has meticulously developed core key technologies for single-port surgical robots. Leveraging the innovative “dual-continuum mechanism” design, the company launched the SHURUI single-port laparoscopic surgical robot equipped with nickel-titanium alloy serpentine surgical arms. This achievement broke the long-standing technological monopoly held by foreign companies. In 2020, it received approval from the Center for Medical Device Evaluation of the National Medical Products Administration, becoming China’s first single-port surgical robot to pass the special review procedure for innovative medical devices. The SHURUI single-port surgical robot offers advantages such as minimally invasive incisions, greater operational flexibility, and enhanced intraoperative stability, and can be applied in multiple clinical fields including urology, gynecology, general surgery, thoracic surgery, and cardiac surgery.

Currently, SHURUI’s single-port laparoscopic surgical robot has completed the world’s first randomized controlled, multicenter registration clinical trial for a single-port serpentine-arm surgical robot in urology. Furthermore, it has pioneered more than ten innovative surgical procedures across multiple specialties, including gynecology, general surgery, and thoracic surgery. In the future, the company will continue to focus on innovation and breakthroughs in key technologies, accelerate the pace of clinical trials and application promotion, and continuously expand the product’s indications to maximize its clinical value. Moreover, the company will steadily advance the integration of industry, academia, research, and clinical practice, truly ensuring that innovations originate from clinical needs and give back to clinical care. While establishing a strong foothold in the domestic market and promoting China’s independently developed original technologies to benefit the Chinese population, SHURUI Robotics will actively expand into overseas markets, showcasing the strength of intelligent manufacturing in China.

Loyal Valley Capital consistently adheres to the investment philosophy of “long-termism, focus, and altruism.” It is committed to building China’s premier investment research and post-investment management teams, covering three key sectors: technology manufacturing, healthcare, and tech-driven consumer goods. By conducting in-depth industry research and providing proactive post-investment value-added services, Loyal Valley Capital partners with outstanding entrepreneurs to co-create great enterprises that represent the future growth direction of China’s economy and generate value for society.

Since its establishment in 2015, Loyal Valley Capital has invested in a portfolio of outstanding companies that represent the future direction of China’s economic development, including SUPCON Technology, Rigol Technologies, Bayi Space, Avary Holding, O-Net Technologies, UNISOC, Junshi Biosciences, Akeso, InnoCare Pharma, Obio Technology, CARsgen Therapeutics, Henlius, Bilibili, ByteDance, POP MART, NetEase Cloud Music, and Jiangxiaobai, among more than 70 leading enterprises.